Enlivex Therapeutics Ltd
NASDAQ:ENLV

Watchlist Manager
Enlivex Therapeutics Ltd Logo
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Watchlist
Price: 0.96 USD -5.88%
Market Cap: 23.3m USD

Enlivex Therapeutics Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Enlivex Therapeutics Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Enlivex Therapeutics Ltd
NASDAQ:ENLV
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Kamada Ltd
NASDAQ:KMDA
Revenue
$174.8m
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
10%
Urogen Pharma Ltd
NASDAQ:URGN
Revenue
$96.5m
CAGR 3-Years
16%
CAGR 5-Years
91%
CAGR 10-Years
N/A
Entera Bio Ltd
NASDAQ:ENTX
Revenue
$124k
CAGR 3-Years
-25%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Pluri Inc
NASDAQ:PLUR
Revenue
$1.3m
CAGR 3-Years
60%
CAGR 5-Years
125%
CAGR 10-Years
13%
M
Matricelf Ltd
TASE:MTLF
Revenue
₪0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Enlivex Therapeutics Ltd
Glance View

Market Cap
23.3m USD
Industry
Biotechnology

Enlivex Therapeutics Ltd. develops autologous and allogeneic drug pipeline for treatment of autoimmune and inflammatory conditions. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

ENLV Intrinsic Value
0.75 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Enlivex Therapeutics Ltd's Revenue?
Revenue
0 USD

Based on the financial report for Sep 30, 2025, Enlivex Therapeutics Ltd's Revenue amounts to 0 USD.

Back to Top